Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the patient journey during CAR T-cell therapy, from apheresis to CAR T-cell infusion, including the manufacturing process. Prof. Mohty explains cytokine-release syndrome (CRS) and highlights the need for a close follow-up and monitoring after treatment. Even though CAR T-cell therapy journey is long, the results are promising and bring hope to patients with relapsed/refractory diseases.